Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197091 · ClinicalTrials.gov registry record
Communication Effectiveness in Cancer Treatment
A clinical trial of Malignant Neoplasm, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT02197091 is a study of Malignant Neoplasm that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02197091, a study of Malignant Neoplasm, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot research trial studies communication effectiveness in cancer treatment. Studying how well patients and their doctors communicate about the treatment being given for cancer may help improve the decisions that patients and physicians make together.
Conditions Studied
Interventions
- OTHER medical chart review
- OTHER questionnaire administration
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02197091
The ClinicalTrials.gov registry entry for NCT02197091 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (80% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which medical chart review is the first listed.
NCT02197091 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02197091 about?
NCT02197091 is a clinical study titled "Communication Effectiveness in Cancer Treatment". This pilot research trial studies communication effectiveness in cancer treatment. Studying how well patients and their doctors communicate about the treatment being given for cancer may help improve the decisions that patients and physicians make together.
What is the current status of trial NCT02197091?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2014-07. Estimated completion is 2016-03.
What conditions does trial NCT02197091 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT02197091?
The interventions under investigation include: medical chart review (OTHER), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT02197091?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02197091 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.